Literature DB >> 19307951

Xerostomia in long-term survivors of aggressive non-Hodgkin's lymphoma of Waldeyer's ring: a potential role for parotid-sparing techniques?

Daniel T Chang1, Robert J Amdur, Heather Pacholke, Nancy P Mendenhall, Christopher G Morris, Gracie A Byer, Kenneth R Olivier.   

Abstract

BACKGROUND: The degree of xerostomia in patients treated for intermediate-and high-grade non-Hodgkin lymphoma (NHL) of Waldeyer's ring (WR) is unknown. METHODS AND MATERIALS: Fifteen patients treated for stage I-IV NHL of WR with radiotherapy (RT) were administered a xerostomia questionnaire. Numerical responses (0 = no xerostomia; 100 = maximum xerostomia) were compared with responses from 5 sets of patients treated for head and neck squamous cell carcinoma who were grouped by amount of parotid in RT field: larynx-only, ipsilateral parotid, bilateral-partial parotid, bilateral-total parotid, parotid-sparing intensity-modulated radiotherapy.
RESULTS: Waldeyer's patients' median xerostomia questionnaire score was 31, which was significantly different from the larynx-only group, bilateral-partial parotid group, and bilateral-total parotid group, but not significantly different from the ipsilateral parotid group or parotid-sparing intensity-modulated radiotherapy group.
CONCLUSIONS: Xerostomia in survivors WR NHL is a detectable toxicity with severity like that in head and neck squamous cell carcinoma patients who receive ipsilateral parotid irradiation, and warrants parotid-sparing RT techniques.

Entities:  

Mesh:

Year:  2009        PMID: 19307951     DOI: 10.1097/COC.0b013e3181841f42

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  3 in total

1.  Late effects in survivors treated for lymphoma as adolescents and young adults: a population-based analysis.

Authors:  Andrea C Lo; Ben Chen; Vanessa Samuel; Kerry J Savage; Ciara Freeman; Karen Goddard
Journal:  J Cancer Surviv       Date:  2021-01-16       Impact factor: 4.442

2.  A poor prognostic case of peripheral T-cell lymphoma in the base of tongue with chemotherapy followed by radiation therapy.

Authors:  Jun-Ho Lee; Seok Ho Lee
Journal:  Springerplus       Date:  2014-12-13

3.  Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.

Authors:  Jia Jin; Dongmei Ji; Zuguang Xia; Kai Xue; Qunling Zhang; Yizhen Liu; Junning Cao; Xiaonan Hong; Juan J Gu; Ye Guo; Fangfang Lv
Journal:  BMC Cancer       Date:  2022-04-13       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.